ZYBT

Company Overview — What Does Zhengye Biotechnology Holding Ltd Do?

We, through the operating entity, focus on the research, development, manufacturing and sales of veterinary vaccines, with an emphasis on vaccines for livestock. For nearly 20 years, the operating entity has been committed to enhancing the health of livestock. The operating entity markets a diverse range of vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs. The operating entity’s products are available in 29 provincial regions across China and are exported overseas, to Vietnam, Pakistan, and Egypt. Our principal executive offices are located at No.1 Lianmeng Road, Jilin Economic & Technical Development Zone, Jilin Province, China. Our registered office in the Cayman Islands is located at 3-212 Governors Square, 23 Lime Tree Bay Avenue, P.O. Box 30746, Seven Mile Beach, Grand Cayman KY1-1203, Cayman Islands. Our agent for service of process in the United States is Cogency Global Inc., located at 122 East 42nd Street, 18th Floor, New York, NY 10168. Zhengye Biotechnology Holding Ltd (ZYBT) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Songlin Song and employs approximately 278 people. With a market capitalization of $40M, ZYBT is one of the notable companies in the Healthcare sector.

Zhengye Biotechnology Holding Ltd (ZYBT) Stock Rating — Reduce (April 2026)

As of April 2026, Zhengye Biotechnology Holding Ltd receives a Reduce rating with a composite score of 36.2/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.ZYBT ranks #3,124 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Zhengye Biotechnology Holding Ltd ranks #426 of 839 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ZYBT Stock Price and 52-Week Range

Zhengye Biotechnology Holding Ltd (ZYBT) currently trades at $0.88. Recent trading volume was 0 shares, suggesting relatively thin trading activity.

Is ZYBT Overvalued or Undervalued? — Valuation Analysis

Zhengye Biotechnology Holding Ltd (ZYBT) carries a value factor score of 78/100 in the Blank Capital model, suggesting the stock trades at a meaningful discount to its fundamental earning power. The trailing price-to-earnings ratio is 214.46x, compared to the Healthcare sector average of 23.29x — a premium of 821%. The price-to-book ratio stands at 1.10x, versus the sector average of 2.69x. The price-to-sales ratio is 0.42x, compared to 1.64x for the average Healthcare stock. On an enterprise value basis, ZYBT trades at 2.25x EV/EBITDA, versus 6.36x for the sector.

Based on these multiples, Zhengye Biotechnology Holding Ltd appears attractively valued relative to both its sector peers and the broader market. Value-oriented investors may find the current entry point compelling, particularly if the company's fundamental quality metrics also score well.

Zhengye Biotechnology Holding Ltd Profitability — ROE, Margins, and Quality Score

Zhengye Biotechnology Holding Ltd (ZYBT) earns a quality factor score of 38/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 19.0%, compared to the Healthcare sector average of -42.5%, which is within a healthy range. Return on assets (ROA) comes in at 10.9% versus the sector average of -33.1%.

On a margin basis, Zhengye Biotechnology Holding Ltd reports gross margins of 49.0%, compared to 71.3% for the sector. The operating margin is 8.8% (sector: -65.2%). Net profit margin stands at 7.2%, versus -54.1% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ZYBT Debt, Balance Sheet, and Financial Health

Zhengye Biotechnology Holding Ltd has a debt-to-equity ratio of 30.0%, compared to the Healthcare sector average of 31.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. Total debt on the balance sheet is $12M. Cash and equivalents stand at $3M.

ZYBT has a beta of 1.88, meaning it is more volatile than the broader market — a $10,000 investment in ZYBT would be expected to move 88.3% more than the S&P 500 on any given day. The stability factor score for Zhengye Biotechnology Holding Ltd is 8/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Zhengye Biotechnology Holding Ltd Revenue and Earnings History — Quarterly Trend

In TTM 2026, Zhengye Biotechnology Holding Ltd reported revenue of $26M and earnings per share (EPS) of $0.00. Net income for the quarter was $2M. Gross margin was 49.0%. Operating income came in at $2M.

In FY 2024, Zhengye Biotechnology Holding Ltd reported revenue of $26M and earnings per share (EPS) of $0.00. Net income for the quarter was $2M. Gross margin was 49.0%. Revenue grew -14.4% year-over-year compared to FY 2023. Operating income came in at $2M.

In FY 2023, Zhengye Biotechnology Holding Ltd reported revenue of $30M and earnings per share (EPS) of $0.10. Net income for the quarter was $5M. Gross margin was 55.5%. Operating income came in at $6M.

ZYBT Dividend Yield and Income Analysis

Zhengye Biotechnology Holding Ltd (ZYBT) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ZYBT Momentum and Technical Analysis Profile

Zhengye Biotechnology Holding Ltd (ZYBT) has a momentum factor score of 7/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 64/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 41/100 reflects moderate short selling activity.

ZYBT vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Zhengye Biotechnology Holding Ltd (ZYBT) ranks #426 out of 839 stocks based on the Blank Capital composite score. This places ZYBT in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.5/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.3/100, HOLOGIC INC (HOLX) with a score of 52.8/100, FONAR CORP (FONR) with a score of 53.0/100, and Royalty Pharma plc (RPRX) with a score of 53.4/100.

Comparing ZYBT against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ZYBT vs S&P 500 (SPY) comparison to assess how Zhengye Biotechnology Holding Ltd stacks up against the broader market across all factor dimensions.

ZYBT Next Earnings Date

No upcoming earnings date has been announced for Zhengye Biotechnology Holding Ltd (ZYBT) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ZYBT? — Investment Thesis Summary

The quantitative profile for Zhengye Biotechnology Holding Ltd suggests caution. The quality score of 38/100 flags below-average profitability. The value score of 78/100 suggests attractive pricing relative to fundamentals. Momentum is weak at 7/100, a headwind for near-term performance. High volatility (stability score 8/100) increases portfolio risk.

In summary, Zhengye Biotechnology Holding Ltd (ZYBT) earns a Reduce rating with a composite score of 36.2/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ZYBT stock.

Related Resources for ZYBT Investors

Explore more research and tools: ZYBT vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ZYBT head-to-head with peers: ZYBT vs AZN, ZYBT vs SLGL, ZYBT vs HOLX.